Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

Mohammad Ullah Nayan, Sudipta Panja, Ashrafi Sultana, Lubaba A. Zaman, Lalitkumar K. Vora, Brady Sillman, Howard Eliot Gendelman, Benson Edagwa

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs hold promise for improved regimen adherence and reduced toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is safe and effective. Alternative promising DDSs include implants, prodrugs, vaginal rings, and microarray patches. Each can further meet patients’ needs. We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.

Original languageEnglish (US)
Article number183
Issue number2
StatePublished - Feb 2024


  • antiretroviral therapy
  • chronic infectious diseases
  • HIV
  • implants
  • long-acting formulations
  • microarray patches
  • polymer
  • prodrug nanoformulations
  • vaginal rings

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Polymer Delivery Systems for Long-Acting Antiretroviral Drugs'. Together they form a unique fingerprint.

Cite this